These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30208436)

  • 21. Adherence and the Lie in a HIV Prevention Clinical Trial.
    Stadler J; Scorgie F; van der Straten A; Saethre E
    Med Anthropol; 2016; 35(6):503-516. PubMed ID: 26575611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical issues in trials of preexposure prophylaxis.
    Dunn DT; Glidden DV
    Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PrEP works.
    Jefferys R
    IAVI Rep; 2015; 19(1):4-10, 19. PubMed ID: 26043498
    [No Abstract]   [Full Text] [Related]  

  • 24. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promise and pitfalls of pre-exposure prophylaxis for female sex workers.
    Cowan FM; Delany-Moretlwe S
    Curr Opin HIV AIDS; 2016 Jan; 11(1):27-34. PubMed ID: 26633639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-Exposure Prophylaxis (PrEP): Can HIV be Prevented?
    Salter D
    Ala Nurse; 2015 Dec; 42(4):6. PubMed ID: 26749943
    [No Abstract]   [Full Text] [Related]  

  • 27. Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier.
    Joseph Davey DL; Bekker LG; Gorbach PM; Coates TJ; Myer L
    AIDS; 2017 Oct; 31(16):2193-2197. PubMed ID: 28723709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?
    Pialoux G; Delaugerre C; Cotte L; Raffi F; Cua E; Molina JM
    Clin Microbiol Infect; 2016 Sep; 22(9):757-767. PubMed ID: 27615724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical students reflect on the future of Pre-Exposure Prophylaxis use among adolescents and young adults.
    Eweka I; Fleuriscar J; Fleuriscar J; Adeyemi-Jones A; Dillon B; Albritton T
    Prev Med; 2018 Aug; 113():122-123. PubMed ID: 29792894
    [No Abstract]   [Full Text] [Related]  

  • 30. PrEParing Providers: The Next Challenge in Implementing Human Immunodeficiency Virus Preexposure Prophylaxis.
    Hurt CB
    Sex Transm Dis; 2018 Jul; 45(7):459-461. PubMed ID: 29889161
    [No Abstract]   [Full Text] [Related]  

  • 31. Nondaily preexposure prophylaxis for HIV prevention.
    Anderson PL; García-Lerma JG; Heneine W
    Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions.
    Traeger MW; Patel P; Guy R; Hellard ME; Stoové MA;
    AIDS; 2021 Jan; 35(1):155-157. PubMed ID: 33273185
    [No Abstract]   [Full Text] [Related]  

  • 34. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
    Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness.
    Amico KR
    Curr Opin HIV AIDS; 2012 Nov; 7(6):542-8. PubMed ID: 22964887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
    Mayor S
    BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
    [No Abstract]   [Full Text] [Related]  

  • 39. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.
    Tan DHS; Hull MW; Yoong D; Tremblay C; O'Byrne P; Thomas R; Kille J; Baril JG; Cox J; Giguere P; Harris M; Hughes C; MacPherson P; O'Donnell S; Reimer J; Singh A; Barrett L; Bogoch I; Jollimore J; Lambert G; Lebouche B; Metz G; Rogers T; Shafran S;
    CMAJ; 2017 Nov; 189(47):E1448-E1458. PubMed ID: 29180384
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
    Baker J; OʼHara KM
    JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.